Clinical trial NCT01585623: Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Official title: An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumor
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2012-04-26
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Primary Objective:

* To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4).
* To document pharmacokinetics of SAR302503 after repeated 500 mg oral daily doses.

Secondary Objectives:

* To assess the safety profile of 15-day repeated oral doses of 500 mg SAR302503 in Segment 1
* To characterize the safety and tolerability of 28-day consecutive doses of 500 mg SAR302503 in Segment 2
* To determine antitumor activity in Segment 2

Detailed description: The duration of the study for an individual patient will include a period to assess eligibility (screening period 21 days), followed by a treatment period of at least 15 days of study treatment, and an end-of-treatment visit at least 30 days following the last administration of study drug. However, treatment may continue if patients are receiving benefit and do not have unacceptable toxicity or meet study withdrawal criteria.

Eligibility criteria: Inclusion criteria :

* Histologically or cytologically confirmed advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist
* Signed informed consent

Exclusion criteria:

* Less than 18 years of age.
* Limited physical functioning (as evaluated by the Eastern Cooperative Oncology Group (ECOG) scale)
* Inability to follow study requirements and schedule
* Treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other anti-cancer therapy
* Serious medical illness at same time of study and/or significantly abnormal lab reports
* Lack of pregnancy contraception (women of childbearing potential), pregnancy, or breast feeding.
* Men who partner with a woman of childbearing potential, unless they agree to use effective contraception while on study drug
* Continued toxic effects of prior chemotherapy
* Evidence of other concurrent active malignancy
* Other concurrent serious illness or medical condition
* Cardiac abnormalities include bradycardia, AV block or other conduction defect on ECG, and patients taking a beta blocker.
* Patients with Insulin-Dependent Diabetes Mellitus.
* Patients with known active (acute or chronic) hepatitis A, B, C, and hepatitis B and C carries. Prior history of chronic liver disease (e.g., chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis \[NASH\]).
* Inadequate organ function
* History of partial or total gastrectomy, or, if in the opinion of the investigator, have any other disorder that would inhibit absorption of oral medications.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter: AUC, AUClast
timeFrame: predose and up to 24 hours post dose on Days -1, 1, 15 and 16
Secondary outcomes:
measure: Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter : Cmax, Tmax, and t1/2z
timeFrame: predose and up to 24 hours post dose on Days -1, 1, 15 and 16
measure: SAR302503 - Pharmacokinetic parameter : Cmax, Tmax, Ctrough and AUC0-24
timeFrame: Day-1 to Day 16
measure: Clinical and laboratory events graded by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v4.03 (Segment 1 and 2)
timeFrame: up to maximum 2 years
measure: Objective response ratio (Complete response (CR) and partial response (PR)) (Segment 2)
timeFrame: up to 2 cycles ( i.e. 10 weeks)
Other outcomes:
Locations:
city: Augusta
country: United States
facility: Investigational Site Number 840004
state: Georgia
city: Detroit
country: United States
facility: Investigational Site Number 840001
state: Michigan
city: Philadelphia
country: United States
facility: Investigational Site Number 840002
state: Pennsylvania
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References: